Skip to main content
Erschienen in: European Radiology 8/2019

21.01.2019 | Magnetic Resonance

Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging

verfasst von: Shuling Chen, Shiting Feng, Jingwei Wei, Fei Liu, Bin Li, Xin Li, Yang Hou, Dongsheng Gu, Mimi Tang, Han Xiao, Yingmei Jia, Sui Peng, Jie Tian, Ming Kuang

Erschienen in: European Radiology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Immunoscore evaluates the density of CD3+ and CD8+ T cells in both the tumor core and invasive margin. Pretreatment prediction of immunoscore in hepatocellular cancer (HCC) is important for precision immunotherapy. We aimed to develop a radiomics model based on gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced MRI for pretreatment prediction of immunoscore (0–2 vs. 3–4) in HCC.

Materials and methods

The study included 207 (training cohort: n = 150; validation cohort: n = 57) HCC patients with hepatectomy who underwent preoperative Gd-EOB-DTPA-enhanced MRI. The volumes of interest enclosing hepatic lesions including intratumoral and peritumoral regions were manually delineated in the hepatobiliary phase of MRI images, from which 1044 quantitative features were extracted and analyzed. Extremely randomized tree method was used to select radiomics features for building radiomics model. Predicting performance in immunoscore was compared among three models: (1) using only intratumoral radiomics features (intratumoral radiomics model); (2) using combined intratumoral and peritumoral radiomics features (combined radiomics model); (3) using clinical data and selected combined radiomics features (combined radiomics-based clinical model).

Results

The combined radiomics model showed a better predicting performance in immunoscore than intratumoral radiomics model (AUC, 0.904 (95% CI 0.855–0.953) vs. 0.823 (95% CI 0.747–0.899)). The combined radiomics-based clinical model showed an improvement over the combined radiomics model in predicting immunoscore (AUC, 0·926 (95% CI 0·884–0·967) vs. 0·904 (95% CI 0·855–0·953)), although differences were not statistically significant. Results were confirmed in validation cohort and calibration curves showed good agreement.

Conclusion

The MRI-based combined radiomics nomogram is effective in predicting immunoscore in HCC and may help making treatment decisions.

Key Points

• Radiomics obtained from Gd-EOB-DTPA-enhanced MRI help predicting immunoscore in hepatocellular carcinoma.
• Combined intratumoral and peritumoral radiomics are superior to intratumoral radiomics only in predicting immunoscore.
• We developed a combined clinical and radiomicsnomogram to predict immunoscore in hepatocellular carcinoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S (2015) Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 261:947–955 Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S (2015) Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 261:947–955
2.
Zurück zum Zitat El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389:2492–2502CrossRefPubMedPubMedCentral El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389:2492–2502CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Sangro B, Gomez-Martin C, de la Mata M et al (2013) A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59:81–88CrossRefPubMed Sangro B, Gomez-Martin C, de la Mata M et al (2013) A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59:81–88CrossRefPubMed
5.
Zurück zum Zitat Kim YJ (2015) Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy. Oncoimmunology 3:e954868CrossRefPubMedPubMedCentral Kim YJ (2015) Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy. Oncoimmunology 3:e954868CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Taube JM (2014) Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. Oncoimmunology 11:e963413CrossRef Taube JM (2014) Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. Oncoimmunology 11:e963413CrossRef
7.
Zurück zum Zitat Zhou G, Sprengers D, Boor PPC et al (2017) Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology 153:1107–1119CrossRefPubMed Zhou G, Sprengers D, Boor PPC et al (2017) Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology 153:1107–1119CrossRefPubMed
8.
Zurück zum Zitat Galon J, Mlecnik B, Bindea G et al (2014) Towards the introduction of the ‘immunoscore’ in the classification of malignant tumours. J Pathol 232:199–209CrossRefPubMed Galon J, Mlecnik B, Bindea G et al (2014) Towards the introduction of the ‘immunoscore’ in the classification of malignant tumours. J Pathol 232:199–209CrossRefPubMed
9.
Zurück zum Zitat Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964CrossRefPubMed Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964CrossRefPubMed
10.
Zurück zum Zitat Mahmoud SM, Paish EC, Powe DG et al (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949–1955CrossRefPubMed Mahmoud SM, Paish EC, Powe DG et al (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949–1955CrossRefPubMed
11.
Zurück zum Zitat Brunner SM, Rubner C, Kesselring R et al (2015) Tumor-infiltrating, interleukin-33–producing effector-memory CD8+ T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology 61:1957–1967CrossRefPubMed Brunner SM, Rubner C, Kesselring R et al (2015) Tumor-infiltrating, interleukin-33–producing effector-memory CD8+ T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology 61:1957–1967CrossRefPubMed
12.
Zurück zum Zitat Jiang Y, Zhang Q, Hu Y et al (2018) ImmunoScore signature: a prognostic and predictive tool in gastric cancer. Ann Surg 267:504–513CrossRefPubMed Jiang Y, Zhang Q, Hu Y et al (2018) ImmunoScore signature: a prognostic and predictive tool in gastric cancer. Ann Surg 267:504–513CrossRefPubMed
13.
Zurück zum Zitat Donnem T, Hald SM, Paulsen EE et al (2015) Stromal CD8+ T-cell density-a promising supplement to TNM staging in non-small cell lung cancer. Clin Cancer Res 21:2635–2643CrossRefPubMed Donnem T, Hald SM, Paulsen EE et al (2015) Stromal CD8+ T-cell density-a promising supplement to TNM staging in non-small cell lung cancer. Clin Cancer Res 21:2635–2643CrossRefPubMed
14.
Zurück zum Zitat Gabrielson A, Wu Y, Wang H et al (2016) Intratumoral CD3 and CD8 T-cell densities associated with relapse free survival in HCC. Cancer Immunol Res 4:419–430CrossRefPubMedPubMedCentral Gabrielson A, Wu Y, Wang H et al (2016) Intratumoral CD3 and CD8 T-cell densities associated with relapse free survival in HCC. Cancer Immunol Res 4:419–430CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Sun C, Xu J, Song J et al (2015) The predictive value of centre tumour CD8+ T cells in patients with hepatocellular carcinoma: comparison with immunoscore. Oncotarget 6:35602–35615PubMedPubMedCentral Sun C, Xu J, Song J et al (2015) The predictive value of centre tumour CD8+ T cells in patients with hepatocellular carcinoma: comparison with immunoscore. Oncotarget 6:35602–35615PubMedPubMedCentral
16.
Zurück zum Zitat Yao Q, Bao X, Xue R et al (2017) Prognostic value of immunoscore to identify mortality outcomes in adults with HBV-related primary hepatocellular carcinoma. Medicine (Baltimore) 96(17):e67356CrossRef Yao Q, Bao X, Xue R et al (2017) Prognostic value of immunoscore to identify mortality outcomes in adults with HBV-related primary hepatocellular carcinoma. Medicine (Baltimore) 96(17):e67356CrossRef
17.
Zurück zum Zitat Garnelo M, Tan A, Her Z et al (2017) Interaction between tumor-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut 66:342–351CrossRefPubMed Garnelo M, Tan A, Her Z et al (2017) Interaction between tumor-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut 66:342–351CrossRefPubMed
19.
Zurück zum Zitat Ku YJ, Kim HH, Cha JH et al (2016) Correlation between MRI and the level of tumor-infiltrating lymphocytes in patients with triple negative breast cancer. AJR Am J Roentgenol 207:1146–1151CrossRefPubMed Ku YJ, Kim HH, Cha JH et al (2016) Correlation between MRI and the level of tumor-infiltrating lymphocytes in patients with triple negative breast cancer. AJR Am J Roentgenol 207:1146–1151CrossRefPubMed
20.
Zurück zum Zitat Ku YJ, Kim HH, Cha JH et al (2018) Predicting the level of tumor-infiltrating lymphocytes in patients with triple negative breast cancer: usefulness of breast MRI computer-aided detection and diagnosis. J Magn Reson Imaging 47:760–766CrossRefPubMed Ku YJ, Kim HH, Cha JH et al (2018) Predicting the level of tumor-infiltrating lymphocytes in patients with triple negative breast cancer: usefulness of breast MRI computer-aided detection and diagnosis. J Magn Reson Imaging 47:760–766CrossRefPubMed
22.
Zurück zum Zitat Sun R, Limkin EJ, Dercle L et al (2017) Computational medical imaging (radiomics) and potential for immuno-oncology. Cancer Radiother 21:648–654CrossRefPubMed Sun R, Limkin EJ, Dercle L et al (2017) Computational medical imaging (radiomics) and potential for immuno-oncology. Cancer Radiother 21:648–654CrossRefPubMed
24.
Zurück zum Zitat Li Y, Liu X, Xu K et al (2018) MRI features can predict EGFR expression in lower grade gliomas: a voxel-based radiomic analysis. Eur Radiol 28:356–362CrossRefPubMed Li Y, Liu X, Xu K et al (2018) MRI features can predict EGFR expression in lower grade gliomas: a voxel-based radiomic analysis. Eur Radiol 28:356–362CrossRefPubMed
25.
26.
Zurück zum Zitat Braman NM, Etesami M, Prasanna P et al (2017) Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res 19:57CrossRefPubMedPubMedCentral Braman NM, Etesami M, Prasanna P et al (2017) Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res 19:57CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Rutman AM, Kuo MD (2009) Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol 70:232–241CrossRefPubMed Rutman AM, Kuo MD (2009) Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol 70:232–241CrossRefPubMed
29.
Zurück zum Zitat Hamm B, Staks T, Mühler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792CrossRefPubMed Hamm B, Staks T, Mühler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792CrossRefPubMed
30.
Zurück zum Zitat Choi JW, Lee JM, Kim SJ et al (2013) Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR images and their value as an imaging biomarker. Radiology 267:776–786CrossRefPubMed Choi JW, Lee JM, Kim SJ et al (2013) Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR images and their value as an imaging biomarker. Radiology 267:776–786CrossRefPubMed
31.
Zurück zum Zitat Zhang B, Tian J, Dong D et al (2017) Radiomics features of multiparametric MRI as novel prognostic factors in advanced nasopharyngeal carcinoma. Clin Cancer Res 23:4259–4269CrossRefPubMed Zhang B, Tian J, Dong D et al (2017) Radiomics features of multiparametric MRI as novel prognostic factors in advanced nasopharyngeal carcinoma. Clin Cancer Res 23:4259–4269CrossRefPubMed
32.
Zurück zum Zitat Bakr S, Echegaray S, Shah R et al (2017) Noninvasive radiomics signature based on quantitative analysis of computed tomography images as a surrogate for microvascular invasion in hepatocellular carcinoma: a pilot study. J Med Imaging (Bellingham) 4:041303 Bakr S, Echegaray S, Shah R et al (2017) Noninvasive radiomics signature based on quantitative analysis of computed tomography images as a surrogate for microvascular invasion in hepatocellular carcinoma: a pilot study. J Med Imaging (Bellingham) 4:041303
33.
Zurück zum Zitat Huang YQ, Liang CH, He L et al (2016) Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. J Clin Oncol 34:2157–2164CrossRefPubMed Huang YQ, Liang CH, He L et al (2016) Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. J Clin Oncol 34:2157–2164CrossRefPubMed
34.
Zurück zum Zitat Li H, Zhu Y, Burnside ES et al (2016) MR imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of MammaPrint, Oncotype DX, and PAM50 gene assays. Radiology 281:382–391CrossRefPubMed Li H, Zhu Y, Burnside ES et al (2016) MR imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of MammaPrint, Oncotype DX, and PAM50 gene assays. Radiology 281:382–391CrossRefPubMed
35.
36.
Zurück zum Zitat Leijenaar RT, Carvalho S, Velazquez ER et al (2013) Stability of FDG-PET radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol 52:1391–1137CrossRefPubMed Leijenaar RT, Carvalho S, Velazquez ER et al (2013) Stability of FDG-PET radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol 52:1391–1137CrossRefPubMed
37.
Zurück zum Zitat Geurts P, Ernst D, Wehenkel L (2006) Extremely randomized trees. Mach Learn 63:3–42CrossRef Geurts P, Ernst D, Wehenkel L (2006) Extremely randomized trees. Mach Learn 63:3–42CrossRef
38.
Zurück zum Zitat Marée R, Geurts P, Wehenkel L (2007) Random subwindows and extremely randomized trees for image classification in cell biology. BMC Cell Biol 8(Suppl 1):S2CrossRefPubMedPubMedCentral Marée R, Geurts P, Wehenkel L (2007) Random subwindows and extremely randomized trees for image classification in cell biology. BMC Cell Biol 8(Suppl 1):S2CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278:563–577CrossRefPubMed Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278:563–577CrossRefPubMed
40.
Zurück zum Zitat Bourgier C, Colinge J, Aillères N et al (2015) Radiomics: definition and clinical development. Cancer Radiother 19:532–537CrossRefPubMed Bourgier C, Colinge J, Aillères N et al (2015) Radiomics: definition and clinical development. Cancer Radiother 19:532–537CrossRefPubMed
42.
Zurück zum Zitat Fox MJ, Gibbs P, Pickles MD (2016) Minkowski functionals: an MRI texture analysis tool for determination of the aggressiveness of breast cancer. J Magn Reson Imaging 43:903–910CrossRefPubMed Fox MJ, Gibbs P, Pickles MD (2016) Minkowski functionals: an MRI texture analysis tool for determination of the aggressiveness of breast cancer. J Magn Reson Imaging 43:903–910CrossRefPubMed
43.
Zurück zum Zitat Ganeshan B, Goh V, Mandeville HC, Ng QS, Hoskin PJ, Miles KA (2013) Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology 266:326–336 Ganeshan B, Goh V, Mandeville HC, Ng QS, Hoskin PJ, Miles KA (2013) Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology 266:326–336
44.
Zurück zum Zitat Segal E, Sirlin CB, Ooi C et al (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675–680CrossRefPubMed Segal E, Sirlin CB, Ooi C et al (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675–680CrossRefPubMed
Metadaten
Titel
Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging
verfasst von
Shuling Chen
Shiting Feng
Jingwei Wei
Fei Liu
Bin Li
Xin Li
Yang Hou
Dongsheng Gu
Mimi Tang
Han Xiao
Yingmei Jia
Sui Peng
Jie Tian
Ming Kuang
Publikationsdatum
21.01.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 8/2019
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-018-5986-x

Weitere Artikel der Ausgabe 8/2019

European Radiology 8/2019 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.